Acomplia Works For Weight Loss

Rimonabant Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette pangs more manageable. Rimonabant is a new anti-obesity drug, developed by Sanofi-Aventis, a french pharmaceutical company. If you are overweight rimonabant weight loss drug may help you shed pounds.As per recent marketing survey, it shows Approximately 300,000 adult deaths in the United States each year are attributable to unhealthy dietary habits and physical inactivity or sedentary behavior
� Nearly two-thirds of U.S. adults are overweight (BMI > 25, which includes those who are obese).
� Nearly one-third of U.S. adults are obese (BMI > 30).
Obesity: Obesity refers specifically to having an abnormally high proportion of body fat. Individuals with a BMI of 30 or more are considered obese.
Rimonabant Working
Rimonabant works by blocking certain chemical pathways within the brain which make you feel hungry. The drug binds to special chemical receptors in the brain known as endocannabinoid receptors. This binding renders these receptors unresponsive to stimulation by chemicals known as �cannabinoids�.
In other words it should help suppress your appetite. The end result is you eat less and lose weight

Rimonabant Dosage

When talking about the dosage of Zimulti Rimonabant, the most important thing that you need to follow and consider is the directions given by your doctor. This diet pill is widely available in two dosages (10 mg and 20 mg). Very often the physicians do prescribe the 20mg dosage.

Rimonabant Side Effects

Rimonabant Side effects observed during the trials include nausea, dizziness, anxiety and painful joints. A full list of side effects wil
l be available when Rimonabant drug is prescribed to you. We do not know as yet if there will be any influence on the mental state as the endocannabinoid system is yet to be fully evaluated.

Rimonabant : No More Obesity

An obese not only struggle against his excessive weight but also faces threats like diabetes, high blood pressure, high cholesterol to name a few. He wants to lead a healthy life but in spite of several endeavors ended up with zero. When all possibilities of a slim trim figure seem faded, comes Rimonabant diet pill, the miracle drug manufactured by Sanofi-Aventis.

Chantix Smoking Stats

Smoking kills 400,000 people a year in the United States alone, that�s almost 1,100 every day. The figures for the UK are around 121,000 people a year, or approximately 330 per day. Approximately 38% die of cancer, 28% die a slow and agonizing death from chronic lung disease and emphysema, and the other 34% die of heart disease and other circulatory problems.

Smoking is one of the major causes of male impotence, increasing the risk of erective dysfunction by some 50%, and affecting as many as 120,000 males in the UK alone. It has been reported that a male experiencing erectile dysfunction, should take this as a warning that blood vessels are being damaged, and this includes the blood vessels in and around the heart.

Other Weight Loss Resources
Acomplia
Acomplia diet pill

Source:-www.content-articles.com

Born For Weight Loss :Acomplia

It’s been several years in the making and believe-it-or-not it’s been 10-years since a new weight loss drug has been approved, but now there’s a new “kid on the block” and it’s expected to be big news as it represents something of a breakthrough in the management of obesity. The name of this new drug is Acomplia.

Acomplia

Acomplia contains a chemical called Rimonabant and it represents one of the latest and indeed most novel methods for controlling body mass because it operates by being a cannabinoid receptor antagonist. This means that it prevents the normal action of endogenous cannabinoid in the brain from stimulating the so-called CB1 receptors. It would appear that these receptors stimulate appetite and therefore when they are “subdued” so is the need to eat.

The origin of this idea was the realization that smoking cannabis tends to induce the sensation to eat, the so-called munchies. This lead scientists to believe that the inhibition of the cannabinoid receptors may lead to the opposite effect. There must have been some interesting proposals as to how to conduct the clinical trials!

So it was the pharmaceutical giant Sanofi-Aventis that set out in 2001 to begin clinical trials to establish whether this approach could benefit obese individuals. The results of those trials have resulted in much excitement and the anticipation of the drug’s release, under the brand name of Acomplia. According to Jean-Francois Dehecq, Sanofi’s CEO, Acomplia Diet pill could peak annual sales of $3.6 billion an amount unheard of, even in the lucrative market of weight loss treatments.

So what’s all the fuss about? Let’s look at some of the clinical trials.

Weight loss

Findings of a human 2-year trial with Acomplia were presented at the American Heart Association conference in New Orleans in November 2004. It indicated that 33% of people using Acomplia managed to lose 10% of their body weight and kept their weight down throughout the study period of 2-years, a further third lost 5% of their body weight and kept that weight off too.

Additional long term human study results were presented in March 2005 at the American College of Cardiology. 1036 patients who were either overweight or obese and who also had blood lipid disorders were randomized to one of three groups, those being placebo, 5 mg./ day or 20 mg./ day of Acomplia. After 1-year of treatment, patients receiving 20 mg./ day Acomplia had significant improvements (compared to placebo) in waist circumference, as well as HDL (good cholesterol) levels, triglyceride levels, CRP levels and insulin sensitivity.

During the trial the drug was well tolerated. The only relatively common side effects were mild gastrointestinal effects, dizziness and these were noted to be transient.

“Those who stay on the drug for a year show remarkable weight loss: on average 17 pounds (7.7 Kg).” said Jean Pierre Despres, PhD., Professor of food and nutrition sciences at Lavel University in Montreal. “Plus we saw a real reduction in waist circumference of 3 inches (8 cm).”

But aside from the weight loss, the numerous trials conducted to date have also highlighted other possible advantages for Acomplia.

Source:-www.antiaging-systems.com